Acute Promyelocytic Leukemia

specific

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML), and it is treated differently than other types of AML because of its marked sensitivity to differentiating effects of all trans-retinoic acid. APL is characterized by a severe coagulopathy which may be present at diagnosis. APL occurs in 7 % of children with AML.

29

Centers

14

Active Trials

$10M

Cancer Funding

Top Centers for Acute Promyelocytic Leukemia(29)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
NCI Comprehensive
High-Volume Research Center
80.3
277.8
3
NCI Comprehensive
High-Volume Research Center
74.2
4
NCI Comprehensive
Active Research Program
59.7
5
NCI Comprehensive
Active Research Program
59.7
6
NCI Comprehensive
Active Research Program
59.7
7
Masonic Cancer CenterMinneapolis, MN
NCI Comprehensive
Active Research Program
59.7
8
NCI Comprehensive
Active Research Program
59.7
9
NCI Comprehensive
Active Research Program
59.7
10
NCI Comprehensive
Active Research Program
59.7
11
Active Research Program
59.7
12
Active Research Program
59.7
13
Active Research Program
59.7
14
Active Research Program
59.7
15
NCI Comprehensive
Active Research Program
56.6
16
NCI Comprehensive
Active Research Program
54.1
17
NCI Comprehensive
Active Research Program
52.9
18
NCI Comprehensive
37.2
19
NCI Comprehensive
37.2
20
NCI Comprehensive
37.2
2137.2
22
NCI Comprehensive
37.2
23
NCI Comprehensive
37.2
24
NCI Comprehensive
37.2
25
NCI Comprehensive
37.2
26
NCI Comprehensive
37.2
27
NCI Comprehensive
37.2
2837.2
2937.2

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →